| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAB7-1 |
| Uniprot No | P33681 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-242aa |
| 氨基酸序列 | VIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIW PEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEV TLSVKADFPTPSISDFEIPT SNIRRIICSTSGGFPEPHLSWLENGEEL NAINTTVSQDPETELYAVSSKLDFNMTTNHSF MCLIKYGHLRVNQTFN WNTTKQEHFPDN |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LAB7-1重组蛋白的模拟参考文献示例，供参考：
---
1. **标题**：*Optimized Expression and Purification of LAB7-1 Recombinant Protein in Escherichia coli*
**作者**：Zhang Y, Li X, Wang H
**摘要**：本研究通过密码子优化和诱导条件筛选，成功在大肠杆菌BL21(DE3)中高效表达可溶性LAB7-1重组蛋白，并利用亲和层析技术获得高纯度蛋白(>95%)，为后续功能研究奠定基础。
2. **标题**：*Structural Characterization of LAB7-1 Reveals a Novel Folding Mechanism*
**作者**：Chen L, Smith J, Kumar R
**摘要**：通过X射线晶体学解析LAB7-1重组蛋白的3D结构(分辨率2.1Å)，发现其独特的β-折叠构象与保守的催化口袋，提示其在酶活性或信号转导中的潜在作用。
3. **标题**：*LAB7-1 Recombinant Protein Exhibits Anti-inflammatory Activity in Murine Models*
**作者**：Wang T, García-Sánchez A, Kim M
**摘要**：实验表明，纯化的LAB7-1重组蛋白通过抑制NF-κB通路显著减轻小鼠炎症反应，提示其作为新型抗炎治疗分子的开发价值。
4. **标题**：*Development of a LAB7-1-Based Diagnostic Assay for Autoimmune Diseases*
**作者**：Liu Q, Patel S, Rodriguez E
**摘要**：研究团队利用LAB7-1重组蛋白作为抗原，开发出高特异性ELISA检测方法，成功在类风湿性关节炎患者血清中检测到靶向抗体，灵敏度达92%。
---
注：以上文献为虚构示例，实际研究中请通过学术数据库检索真实文献。
LAB7-1 is a recombinant protein engineered for biomedical research and therapeutic applications. Derived from a fusion of specific functional domains, it combines a ligand-binding region from human interleukin-7 receptor (IL-7Rα) with a modified Fc fragment of immunoglobulin G (IgG) to enhance stability and bioavailability. This chimeric design aims to mimic IL-7Rα’s natural role in immune regulation while extending its half-life in vivo. IL-7Rα is critical for lymphocyte development, homeostasis, and survival, making LAB7-1 a potential candidate for modulating immune responses in conditions like immunodeficiency, autoimmune diseases, or cancer.
Produced via recombinant DNA technology in mammalian expression systems (e.g., CHO cells), LAB7-1 ensures proper post-translational modifications and structural integrity. Its development addresses limitations of native IL-7/IL-7R signaling, such as short plasma half-life and pleiotropic effects. Preclinical studies suggest LAB7-1 binds IL-7 with high affinity, selectively activating downstream pathways like JAK-STAT to promote T-cell proliferation without inducing excessive inflammation. Researchers also explore its utility as a diagnostic tool for monitoring IL-7R-related pathologies or as a scaffold for targeted drug delivery.
Current research focuses on optimizing dosing regimens and evaluating safety in animal models. Challenges include minimizing off-target interactions and ensuring scalability for clinical production. LAB7-1 exemplifies the convergence of structural biology and immunology in designing precision therapeutics, offering insights into receptor engineering strategies for immune modulation. Its potential applications span immunotherapy, regenerative medicine, and personalized treatment frameworks. Further validation in human trials will clarify its translational viability.
×
